Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The radioimmunological method was used to measure the serum levels of 4 tumour markers--CEA, TPA, Ca 19-9 and Ferritin--in 20 hepatitis patients. Blood levels of bilirubin and transaminase were assayed at the same time. Patients with high levels of bilirubin and transaminase also revealed pathological levels of all 4 markers, especially TPA and ferritin which fell towards normal levels once the acute attack was over.
 ...
PMID:[Course of the serum determination of 4 tumor markers in viral hepatitis]. 347 7

The study of tumor markers in breast cancer tissue may supply information on the tumor's biological features and its clinical behaviour. Forty-nine primary breast cancer patients are evaluable to date. CEA, ferritin, TPA and CA15/3 were measured with radioimmunometric methods in the cytosol of carcinoma and normal tissue from the same breast. The concentrations of the four markers were higher in the tumor than in normal tissue in 42/49 cases for CEA, 47/49 for ferritin, 42/49 for TPA and in 24/29 for CA15/3. However, an overlap was found between carcinoma and normal tissue levels, particularly for CEA and TPA. We can conclude that the four substances studied may be markers of malignancy in breast carcinoma when non-malignant breast tissue from the same patient is determined at the same time, whereas assays within a single, unknown breast tissue sample may be useful only in the case of ferritin and, partly, CA15/3.
 ...
PMID:Carcinoembryonic antigen, ferritin, tissue polypeptide antigen, and CA15/3 in breast cancer: relationship between carcinoma and normal breast tissue. 348 Mar 22

Updated results of a prospective study assessing the value of tumor marker determinations in a supposedly healthy population (2,000) for identification of a group at risk for cancer are reported. With observation periods varying from 1 to 6 years (mean 3.5 years), repeated determinations by RIA were routinely carried out for CEA, AFP, beta-HCG, beta 2-M, ferritin, and, more recently, beta 1-SP. Preliminary data on TPA, CA 12-5, and CA 19-9 were also obtained. A comparative study of methods for CEA determination using monoclonal and polyclonal antibodies revealed that preference should be given to polyclonal antibodies. In the group considered to be "at risk" (ie, having at least one abnormal marker value) (N = 481), the cancer detection rate was 29 per 1,000 against 3.2 per 1,000 in the normal group (N = 1,519). These figures were significant, even if the number of malignancies detected was small (N = 27). By associating general tumor markers such as CEA, TPA, and CA 19-9 with site-specific markers such as PAP and CA 12-5, it seemed that marker determinations played a useful role in risk assessment in cancer detection programs.
 ...
PMID:Tumor markers for cancer detection. II. 349 Sep 9

Twenty patients with lung cancer were treated with a streptococcal preparation, OK-432 in addition to various other treatments, and we evaluated the effect of OK-432 in comparison with an equivalent number of patients without OK-432. With regard to advanced-stage patients, the median survival time of those treated with OK-432 was longer than that of patients without OK-432. Patients whose PPD or SU-PS skin reactions were positive had a longer survival time than those giving a negative reaction. OK-432 significantly increased the reactions for both PPD and SU-PS. On the other hand, OK-432 did not have any significant effect in increasing the numbers of peripheral lymphocytes and T-cell subsets. Furthermore, there were no effects on tumor markers, such as CEA, beta 2-microglobulin and ferritin. However, OK-432 had a remarkable effect in decreasing immunosuppressive acidic protein.
 ...
PMID:[The effect of OK-432 in the treatment of primary lung cancer]. 349 30

Monoclonal antibody F30 was produced by the fusion of murine myeloma cell line P3-X63-Ag8-653 with spleen cells from a BALB/C mouse immunized with established human pancreatic cancer cell line (PK-1) and the reaction specificity was analyzed. The antigen recognized by monoclonal antibody F30 was different from HLA-associated antigen, beta 2-microglobulin, fetal bovine serum components, ferritin, AFP, or CEA. Monoclonal antibody F30 reacted with all of six pancreatic cancer cell lines established in our laboratory. Cross-reactivity was detected with a colon cancer cell line or an esophagus cancer cell line among various tumor cell lines tested. No reaction was detected with red blood cells, lymphocytes, or lymphoid and myeloid cell lines. By immunoperoxidase staining of frozen sections, the F30-defined antigen was detected not only on pancreatic cancer cell membrane but also on other adenocarcinomas. In addition, the monoclonal antibody F30 had a more wide-spread distribution on normal epithelial cells in the gastrointestinal organs, respiratory system, and urinary system. F30-defined antigen was composed of two protein components with molecular weight of 190 and 160 K. It was indicated that the antigen was an integral protein in the cell membrane since the antigen was not detected in the spent culture medium of antigen-positive cells.
 ...
PMID:Human pancreatic cancer associated antigen detected by monoclonal antibody. 351 31

The levels of tumor markers--CEA, ferritin and prolactin (the hormone of the anterior pituitary gland) were studied in the blood serum of 178 breast cancer patients in the menopause during combined therapy using a radioimmunoassay. This combination was shown to be informative for assessment of prognosis of disease and efficacy of antitumor therapy which was confirmed by clinical and x-ray findings and observation of a tumor process in breast cancer patients over a 5-year period.
 ...
PMID:[Radioimmunologic analysis of ferritin, carcinoembryonic antigen and prolactin for evaluating the prognosis and effectiveness of treating breast cancer]. 365 34

The aim of this paper is to determine whether the incidence of estrogen-, progesterone-, CEA-, and ferritin- positive staining of primary tumors, by using the PAP method, is related to the prognosis of breast cancer status. A significantly higher incidence (71 per cent) of CEA-positive tumors was observed in patients who had a recurrence of breast cancer within 2 years after radical operation. Patients, whose tumors were positive in estrogen or negative in CEA, showed a relatively good prognosis, even after a recurrence of the disease. Distant metastases were seen in most of the patients positive in CEA (78 per cent). Before the recurrence of breast cancer, those patients positive in progesterone had a good prognosis. After the recurrence, however, there was no relationship between the prognosis of recurrent disease and the progesterone-staining of primary tumors. Our data suggest that the immunohistological staining of estrogen, progesterone and CEA might offer the effective prognostic indices in breast cancer patients.
 ...
PMID:Immunohistochemical demonstration of estrogen, progesterone, CEA and ferritin in breast cancer and their clinical value for the prediction of early postoperative recurrence. 368 32

Cancer grows in interaction with the host, that is, a host-tumor relationship exists. Investigations of host factors in patients receiving cancer chemotherapy are important, as they reveal the conditions in which a tumor response can develop. Furthermore, reliable host factors, if present, will be useful for quantitative evaluation of the effects of treatment. We have investigated the following three categories of host factors in relation to the effects of cancer chemotherapy and/or immunotherapy. CBC, and blood chemistries (44 parameters). Tumor markers; sialic acid, RNase, lysozyme, ferritin, IAP (immunosuppressive acidic protein), elastase I, AFP, CEA, POA, CA 19-9, CA 125, etc. Immunological parameters; lymphocyte, active T cell, T cell, B cell, IgG Fc receptor-positive T cell, lymphocyte blastogenesis stimulated by PHA, or concanavalin-A, ADCC activity, interferon production in vitro induced by poly I: C, or PHA, PPD skin test, immune complex, immunoglobulin G, A, and M, OKT series 3, 4, 8, 11, 4/8 ratio, antihuman HLA-DR, Leu 11, NK cell activity, etc. From our clinical observations, there were no significant differences in the pretreatment levels of these parameters between responders and non-responders. In responders, there was a tendency for the host factors to show greater degrees of improvement following treatment than in non-responders, but none proved to be reasonably reliable parameters for evaluating therapeutic effects. On the other hand, from our clinical observations on the advanced gastric cancer cases, life span showed a close correlation with tumor regression induced by cancer chemotherapy. Because of these facts, it is only natural that the clinical effects of chemotherapy are currently determined by definite tumor regression.
 ...
PMID:[Host factors in cancer chemotherapy]. 372 33

The auxiliary value of TPA in diagnosing neoplastic diseases was compared to other tumor markers such as CEA, IAP and ferritin. The study population consisted of 59 patients with neoplastic diseases and 75 with benign diseases. The percentages of positive cases for TPA, CEA, IPA and ferritin were 58.9%, 39.0%, 66.7%, and 28.6% in neoplastic diseases and 4.5%, 1.4%, 47.1% and 19.7% in benign diseases, respectively. Both the specificity and sensitivity of TPA were as high as those of CEA. However, the positive rate of TPA was lower than that of CEA in lung cancer patients at stages I and II. TPA was indicated to be a suitable marker for combination assay with CEA in diagnosing neoplastic diseases.
 ...
PMID:[Auxiliary value of TPA in diagnosing neoplastic diseases]. 373 75

The efficiency of the combination of two tumor-associated antigens in recognising head and neck cancer was evaluated. The markers studied were CEA and ferritin by radioimmunoassay. CEA was estimated in 22 controls and 41 head and neck cancer patients. There was no difference in CEA values of controls and head and neck cancer patients, suggesting that CEA was not specific for head and neck malignancies. We measured serum ferritin in 27 controls and 58 patients with head and neck cancer. The mean ferritin level was significantly higher in patients (P less than 0.001) than in normal subjects. The ferritin level in patients with no evidence of clinical disease 8 months after treatment showed approximately normal levels, whereas the levels showed a tendency to increase or remain at high levels in patients with a poor prognosis, giving support to the contention that ferritin may prove to be a valuable adjunct in head and neck cancer.
 ...
PMID:Significance of ferritin as a marker in head and neck malignancies. 382 34


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>